BioMarin Pharmaceutical Inc. (BMRN)

81,97 -9,23 (-10,12%) A partir del 12:13PM EDT. Mercado abierto.

BioMarin Pharmaceutical Inc.

770 Lindaro Street
San Rafael, CA 94901
United States
415 506 6700
https://www.biomarin.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 3401

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Alexander Hardy	President, CEO & Director	1,72M	N/A	1969
Mr. Brian R. Mueller	CFO & Executive VP	1,07M	2,47M	1974
Dr. C. Greg Guyer Ph.D.	Executive VP & Chief Technical Officer	1,11M	N/A	1962
Mr. Jeffrey Robert Ajer	Executive VP & Chief Commercial Officer	1,1M	N/A	1962
Dr. Henry J. Fuchs M.D., Ph.D.	President of Worldwide Research & Development	1,41M	N/A	1958
Ms. Erin Burkhart	Group VP & Chief Accounting Officer	N/A	N/A	1979
Dr. Kevin Eggan Ph.D.	Chief Scientific Officer & Senior VP of Research and Early Development	N/A	N/A	N/A
Traci McCarty	Group Vice President of Investor Relations	N/A	N/A	N/A
Mr. George Eric Davis	Executive VP, Chief Legal Officer, General Counsel & Secretary	1,23M	2,11M	1971
Ms. Humaira Serajuddin	Senior VP & Chief Marketing Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Gobierno corporativo

El ISS Governance QualityScore de BioMarin Pharmaceutical Inc., a día 1 de abril de 2024, es 3. Las puntuaciones base son Auditoría: 1; Tablero: 3; Derechos de los accionistas: 5; Compensación: 5.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.